Project Grant R21CA270428
Award Date
9/5/23
Completion Date
8/31/25
Dollars Obligated
$455K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The National Cancer Institute (NCI), through its Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $1,504,098 Project Grant to the Sloan-Kettering Institute for Cancer Research on May 6, 2025. The grant supports a study to identify genetic determinants of radiation-associated contralateral breast cancer (CBC) and develop a comprehensive integrative model of genetic predisposition to radiation-associated CBC. The research leverages the resources of the WECARE study, a large...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on January 3, 2025, supports a 5-year research project focused on "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
This $2,372,456 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a collaborative research program led by Memorial Sloan Kettering Cancer Center focused on leveraging observational (real-world) data to advance precision oncology. The key products and services to be delivered include: Overcoming methodological barriers in the analysis of observational clinico-genomic data (Project 1) Addressing the role of genetic ancestry...
The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $993,446 Project Grant to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective May 1, 2025, will support the development of statistical and machine learning approaches to decode the regulatory activity underlying disease variants, link variants to genes in relevant cell types, and identify disease-critical gene programs and genomic...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...